Dupilumab for the Treatment of Elderly Moderate to Severe Atopic Dermatitis Patient Complicated with Nephrotic Syndrome:A Case Report
Atopic dermatitis(AD)is a chronic recurrent inflammatory skin disease that can affect patients' quality of life.Dupilumab is the first biologic approved for the treatment of patients with moderate-to-severe AD who do not respond well to topical therapies by blocking interleukin(IL)-4 and IL-13 signaling.At present,there are few reported cases of dupilumab in the treatment of elderly AD patients with kidney disease abroad,and there are no reports in China.This case suggests that dupilumab can be used as an effective and safe treatment for elderly AD patients with kidney disease,but further studies are needed to confirm this.
万方数据
维普
